Cephalon, Inc. (NASDAQ: CEPH) is a U.S. biopharmaceutical company co-founded in 1987 by Dr. Frank Baldino, Jr., a pharmacologist and former scientist with the DuPont Company, who continues to serve as its chairman and chief executive officer. The company's name comes from the adjective "cephalic" meaning "related to the head or brain," and it was established primarily to pursue treatments for neurodegenerative diseases.
Sales revenues reached $2 ...
more
Cephalon, Inc. (NASDAQ: CEPH) is a U.S. biopharmaceutical company co-founded in 1987 by Dr. Frank Baldino, Jr., a pharmacologist and former scientist with the DuPont Company, who continues to serve as its chairman and chief executive officer. The company's name comes from the adjective "cephalic" meaning "related to the head or brain," and it was established primarily to pursue treatments for neurodegenerative diseases.
Sales revenues reached $2 billion in 2008, ranking Cephalon among the leading biopharmaceutical companies in the world. In 2006, industry publication MedAd News named the company one of the ten most respected biotechnology firms in the world. Cephalon employs approximately 2,800 employees. CEO Baldino is paid an annual salary of $1,244,600.
Cephalon is a component of the S&P; MidCap 400 stock index, and was first included in the Fortune 1000 list of U.S. companies based upon annual revenues for 2006. However, as of end-July 2009, CEPH was still trading close to its 52...
less
